HEALTH POLICY BRIEF — Thursday, June 25
HEALTH POLICY BRIEF — Thursday, June 25 — Thursday, June 25, 2026
Executive Briefing
1. HHS-OIG opened a fraud-and-abuse RFI on clinical trial participant remuneration.
Federal Register publication on June 24: OIG is asking whether it should modify or add anti-kickback safe harbors, Beneficiary Inducements CMP exceptions, or guidance for compensation and support offered to clinical trial participants. The questions go straight at travel, lodging, childcare, meals, stipends, cost-sharing subsidies, IRB review, advertising limits, fraud safeguards, and whether existing AKS/CMP uncertainty is suppressing trial participation.
Policy relevance: This is not a health IT item, but it is real federal action with physician/practice and access implications. If OIG creates clearer guardrails, research sites and physician investigators may get more room to reduce participation burden without feeling like every bus voucher is a compliance thundercloud.
Physician policy angle: Worth routing to fraud-and-abuse, research, specialty society, and equity/access colleagues. The practical question is whether physician-led trial sites need clearer safe-harbor protection for reasonable participant support while keeping manufacturers and trial sponsors from turning "access" into a marketing costume.
2. ONC/ASTP's USCDI+ Quality Draft Version 2 comment window is live through July 17.
The eCQI Resource Center says USCDI+ Quality Draft Version 2 was released June 17, with comments accepted through July 17. This is squarely in digital quality measurement and federal data infrastructure territory: the data element list supports quality reporting modernization and sits in the same policy neighborhood as FHIR, eCQMs, specialty registries, and reporting burden.
Policy relevance: Quality data standards look quiet until they harden into measurement, certification, and reporting expectations. Then everyone discovers the workflow implications at implementation time, which is the most expensive time to discover them.
Physician policy angle: Specialty societies and registry stewards should check whether the draft reflects specialty-relevant clinical concepts, avoids unnecessary data capture, and does not quietly shift data-cleanup work onto practices.
Source: https://ecqi.healthit.gov/uscdi-quality-draft-version-2-released
3. HL7 extended the 2026 AI Challenge deadline to July 15.
HL7's AI Challenge page now shows a July 15 deadline. This is not federal rulemaking, but it is a useful standards-community signal: AI tools built around FHIR, CDA, and V2 are moving from theory into demoable implementation.
Policy relevance: For this publication's coverage focus, the value is not the contest itself. It is the implementation pattern: AI adoption will keep leaning on standards, workflow integration, and provenance. Physician-led AI governance needs to stay close to the standards work, not just the agency press releases.
Physician policy angle: Watch for submissions that surface recurring issues around clinical workflow, explainability, safety, liability, data quality, and whether AI outputs can be represented cleanly in interoperable systems.
Source: https://info.hl7.org/ai-challenge
Federal Health Policy Watch
HHS-OIG's clinical trial remuneration RFI is the main federal item today. The June 25 Federal Register/public inspection scan also found a CMS ESRD PPS/AKI dialysis/QIP proposed rule for CY 2027, but the scanner did not surface a concrete digital health, prior authorization, privacy, AI, interoperability, coding, or physician-burden hook for today's brief. It belongs on Watch, not in this publication's morning bloodstream.
Congress / Hearings / Oversight
No fresh high-confidence congressional item crossed the threshold for the main brief. A trade-press/X signal says House Energy and Commerce leaders released compromise Kids Internet and Digital Safety Act text with AI chatbot provisions on June 24, but I did not verify a primary committee post in the morning scan. Treat it as an early privacy/AI signal, not a confirmed health policy action item yet.
Trade source: https://insidehealthpolicy.com/daily-news/bipartisan-energy-and-commerce-panel-leaders-unveil-privacy-bill-ai-chatbot-language
Digital Health / AI / Privacy / Cyber / Interoperability
USCDI+ Quality V2 is the most relevant digital health development today because it has a near-term comment window and a plausible path into quality measurement infrastructure. The X scan also found ONC social signals on draft USCDI+ Sickle Cell Disease data elements and USCDI+ Quality; the Quality item is verified above, while the Sickle Cell item should be verified against the USCDI+ primary page before anyone acts on it.
Prior Authorization / Payer Policy / Administrative Simplification
No new prior authorization development deserves fresh brief space today. The registry scan rediscovered CMS-0062-P, the Interoperability Standards and Prior Authorization for Drugs proposed rule, but the comment period closed June 15. It remains important implementation terrain, especially because CMS proposed October 1, 2027 compliance dates for several drug prior authorization and API-related proposals, but there was no new changed-state hook this morning.
Standards / Coding / Data Infrastructure
USCDI+ Quality V2 and the HL7 AI Challenge are the standards-side watch items. The policy question is whether standards activity is making physician work easier, or merely making the paperwork more computable. That distinction matters.
Signal Scan
The xAI/X scan completed with findings. Usable signals: ONC/USCDI+ Quality, ONC/USCDI+ Sickle Cell Disease, and HL7 AI Challenge deadline movement. No credible X signal changed the strategic picture enough to override primary-source verification. Generic chatter was suppressed.
Policy Action Implications
- Flag the OIG clinical trial remuneration RFI for fraud-and-abuse/research policy review. Decide whether a comment posture is needed around participant support, physician investigator compliance certainty, IRB safeguards, and guardrails against abusive inducement.
- Put USCDI+ Quality V2 on a July 17 standards/data-infrastructure tickler. Check whether registry, specialty, and quality-measure colleagues see missing or burdensome elements.
- Watch HL7 AI Challenge submissions after July 15 for concrete examples that could inform physician-led AI governance, FHIR implementation policy, and digital health policy messaging.
- Do not spend time today on stale CMS prior-auth rediscovery unless someone is specifically tracking post-comment implementation strategy.
Lower-Priority / Watch Only
- CMS CY 2027 ESRD PPS/AKI dialysis/QIP proposed rule: Watch for payment/quality colleagues; no clear this publication-portfolio digital health action hook in today's scan.
- CMS-0062-P drug prior authorization rule: important background, but no new movement today after the June 15 comment deadline.